Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atrasentan · 5 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| atrasentan hydrochloride | DRUG | - |
| Atrasentan | DRUG | - |
DISEASE CHARACTERISTICS: * Diagnosis of hormone-refractory prostate cancer * Completed protocol ABBOTT-M00-211 or ABBOTT-M00-244 within the past 30 days * Disease progression OR * Active in trial when double-blind treatment period ended PATIENT CHARACTERISTICS: Age * 19 and over Performanc...
Top 20 of 53 competitors
Atrasentan is an investigational small molecule being studied for the treatment of prostate cancer, including metastatic and non-metastatic hormone-refractory prostate cancer, as well as hormone-naive prostate cancer with early signs of biochemical failure. It is being developed by Abbott Laboratories (NYSE: ABT) and is currently in Phase 3 clinical development.
Atrasentan is an endothelin receptor antagonist, targeting the endothelin A receptor. This mechanism is being investigated for its potential role in slowing prostate cancer progression. The drug is being developed by Abbott Laboratories (NYSE: ABT) for the treatment of prostate cancer.
Atrasentan is being developed by Abbott Laboratories, traded on the New York Stock Exchange under the ticker ABT. The company is conducting clinical trials to evaluate the drug for the treatment of prostate cancer, including hormone-refractory and hormone-naive forms of the disease.
Atrasentan is in Phase 3 clinical development for prostate cancer, specifically for metastatic and non-metastatic hormone-refractory prostate cancer. It has completed three trials, including two Phase 3 studies and two Phase 2 studies, with a total enrollment of 1,166 participants. The drug is investigational and not yet approved.
Atrasentan has completed several clinical trials, including NCT00036543, a Phase 3 study in men with metastatic hormone-refractory prostate cancer with 1,000 participants, and NCT00036556, a Phase 3 study in non-metastatic hormone-refractory prostate cancer with 941 participants. Additional Phase 2 trials include NCT00038662 and NCT00127478.
Atrasentan is also known as ABT-627, an endothelin receptor antagonist being developed by Abbott Laboratories (NYSE: ABT). It is being studied for the treatment of prostate cancer, including hormone-refractory and hormone-naive forms. The drug is currently in Phase 3 clinical development.